• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Premarket Approval (PMA)

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 


New Search Back to Search Results
Note: This medical device record is a PMA supplement. A supplement may have changed the device description/function or indication from that approved in the original PMA. Be sure to look at the original PMA record for more information.
 
DeviceTRUFILL N-BUTYL CYANOACRYLATE (N-BCA) LIQUID EMBOLIC SYSTEM
Classification Nametissue adhesive for use in embolization of brain arteriovenous malformations
Generic Nametissue adhesive for use in embolization of brain arteriovenous malformations
Applicant
CODMAN & SHURTLEFF, INC.
325 paramount drive
raynham, MA 02767-0350
PMA NumberP990040
Supplement NumberS007
Date Received12/19/2008
Decision Date02/06/2009
Product Code
KGG[ Registered Establishments with KGG ]
Advisory Committee Neurology
Supplement Type30-day notice
Supplement Reason process change - manufacturer/sterilizer/packager/supplier
Expedited Review Granted? No
Combination Product No
Approval Order Statement 
CHANGES AND MODIFICATIONS AS FOLLOWS: 1) THE TRANSFER OF THE MANUFACTURING OF THE TRUFILL N-BCA LIQUID EMBOLIC SYSTEM FROMONE BUILDING TO ANOTHER WITHIN THE SAME FACILITY;2) A CLARIFICATION OF THE INSTRUCTIONS FOR USE (1FU)THE REMOVAL OF A REDUNDANT INCOMING RECEIVING INSPECTION FOR THE N-BCA AND TANTALUMPOUCH;3) THE REMOVAL OF A SPECIFICATION FOR THE N-BCA AND TANTALUM POUCH; AND4) MODIFICATION OF THE SEAL SPECIFICATIONS FOR THE N-BCA AND TANTALUM POUCH.
-
-